



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	09/804,464
Filing Date	March 13, 2001
First Named Inventor	Thomas M. Kundig
Group Art Unit	1651 1644
Examiner Name	TBA Huynh, Phuong
Attorney Docket Number	005184.00002

RECEIVED
FEB 08 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PJK		T. LEHNER, et al., "Targeted Lymph Node Immunization with Simian Immunodeficiency Virus p27 Antigen to Elicit Genital, Rectal, and Urinary Immune Responses in Nonhuman Primates", Journal of Immunology, August 15, 1994, Vol. 153(4)pp. 1858-1868.	*
		B. WALLNER, et al., "Peptide Therapy for Treatment of Allergic Diseases", Clinical Immunology and Immunopathology, Vol. 80, No. 2, August 1996, pp. 105-109	*
		R. VALENTA, et al., "The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases", Int. Arch Allergy Immunology 1998, 116: pp. 167-176	*
		H. MALLING, "Allergen-specific immunotherapy. Present state and directions for the future", Allergy 1999, 54, pp. 30-33.	*
		C. AKDIS, et al., "Immunologic mechanisms of specific immunotherapy", Allergy 1999, 54, 31-32.	*
		E. RAZ, et al., "Deviation of the Allergic IgE to an IgG Response by Gene Immunotherapy", Intern. Rev. Immunol., Vol. 18, pp. 271-289, 1999.	*
		D. LEE, et al., "Inhibition of IgE Antibody Formation by Plasmid DBA Immunization is Mediated by both CD4+ and CD8+ TCells", Int. Arch Allergy Immunol 1997; 113: 227-230.	*
		J. MCGHEE, et al., "Mucosal Th1-versus Th2-Type Responses for Antibody-or Cell-Mediated Immunity to Simian Immunodeficiency Virus in Rhesus Macaques", Journal of Infectious Diseases 1999; 179: pp. S480- S484.	*
		T. LEHNER, et al., "Up-regulation of beta-chemokines and down-modulation of CCR5 receptors inhibit simian immunodeficiency virus transmission human primates" Immunology 2000; 99: pp. 569-577.	*
		S. SHINALL, et al., "Identification of Murine Germinal Center B Cell Subsets Defined Expression of Surface Isotypes and Differentiation Antigens", Journal of Immunology June 1, 2000, Vol. 164(11), pp. 5729-5738.	*
		H. KITAGAKI, et al., "Distinct In Vivo and In Vitro Cytokine Profiles of Draining Lymph Node Cells in Acute and Chronic Phases of Contact Hypersensitivity: Importance of a Type 2 Cytokine-Rich Cutaneous Milieu for the Development of an Early-Type Response in the Chronic Phase", Journal of Immunology, 1999, 163: 1265-1273.	*
↓		A. AUBERTIN, et al., "Generation of CD8+ T Cell-Generation Suppressor Factor and β -Chemokines by Targeted Iliac Lymph Node Immunization in Rhesus Monkeys Challenged with SHIV-89.6P by the Rectal Route", Aids Research and Human Retroviruses 2000, Vol. 16, pp. 381-392.	*

Examiner Signature		Date Considered	7/2/02
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/804,464
Filing Date	March 13, 2001
First Named Inventor	Thomas M. Kundig
Group Art Unit	1651 1644
Examiner Name	TBA PH/Janet N. H...
Attorney Docket Number	005184.00002

RECEIVED

FEB 08 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
PNT		US- 5,612,209	03/18/1997	King	
		US- 5,804,201	09/08/1998	King	
		US- 5,593,877	01/14/1997	King	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
PNT		PCT WO 99/02183	01/21/1999	CTL Immunotherapies Corporation		*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PNT		L. PARIJS, et al., "Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off", Science, Vol. 280, April 10, 1998, pp. 243-248.	*
		R. TEPPER, et al., "IL-4 Induces Allergic-like Inflammatory Disease and Alters T Cell Development in Transgenic Mice", Cell, Vol. 62, August 10, 1990, pp. 457-467.	*
		P. MARK, et al., "Human T and B cell immune responses to Fel d 1 in cat-allergic and non-cat-allergic subjects", Clinical and Experimental Allergy, Vol. 26, 1996, pp. 1316-1328.	*
		A. HELBLING, et al., "Allergy to honey: relation to pollen and honey bee allergy", Allergy, Vol. 47, February 1992, pp. 41-49.	*
		M. dos REIS, et al., "Acute Renal Failure in Experimental Envenomation with Africanized Bee Venom", Renal Failure, Vol. 20, 1998, pp. 39-51.	*
		A DIRKSEN, et al., "Common Components in Pollen Extracts", Allergy, Vol. 35, 1980, pp. 611-616.	*
		H. de GROOT, et al., "Allergy to bumblebee venom I. Occupational anaphylaxis to bumblebee venom: diagnosis and treatment", Allergy, Vol. 50, 1995, pp. 581-584.	*
		T. LEHNER, et al., "Induction of Mucosal and Systemic Immunity to a Recombinant Simian Immunodeficiency Viral Protein", Science, Vol. 258, November 20, 1992, pp. 1365-1369.	*
✓		T. LEHNER, et al., "Mucosal Model of Genital Immunization in Male Rhesus Macaques with a Recombinant Simian Immunodeficiency Virus p27 Antigen", Journal of Virology, Vol. 68, March 1994, pp. 1624-1632.	*

T.M. Kundig

7/2/02